Boston-based Memento Medicines closed a $93 million Series A round on June 18, 2026, to push a bispecific antibody therapy for retinal diseases into development. The round was co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with Sanofi Ventures and Samsara BioCapital also participating — a syndicate that signals serious institutional conviction in both the science and the commercial opportunity.
The Asset: One Antibody, Two Targets
The capital is earmarked to advance MMT-205, a bispecific antibody that simultaneously activates Tie2 and inhibits VEGF. Both are clinically validated targets with known roles in retinal and vascular disease pathogenesis. Combining them in a single molecule is the central bet: the hypothesis is that hitting Tie2 and VEGF together does something neither approach can do alone.
MMT-205 was previously designated MT-103, so it arrives with a development history rather than starting from a blank page. That matters for a Series A — investors are funding a molecule with prior data, not a platform concept.
The License: Korean Biotechs Bring the Molecule, Memento Brings the Capital
Alongside the financing, Memento entered an exclusive worldwide license agreement with MabTics Co., Ltd. and Curacle Co., Ltd., the Korean biotechs that originated the asset. MabTics and Curacle took upfront consideration in the form of both cash and equity in Memento, giving them skin in the outcome rather than a clean exit. They remain eligible for additional payments tied to development, regulatory, and commercial milestones, plus tiered royalties on net sales.
That structure is worth noting. The Korean originators didn't sell outright — they converted into Memento stakeholders while retaining downstream economics. If MMT-205 reaches commercialization, MabTics and Curacle participate in the upside. If it fails, they absorb that alongside the Series A investors. The alignment is tighter than a standard licensing handoff.
What's at Stake in Retinal Disease
The retinal disease market is already home to some of the highest-revenue biologics in ophthalmology, built largely on VEGF inhibition. The commercial question for MMT-205 isn't whether there's a market — it's whether a bispecific approach can demonstrate meaningfully better outcomes than established VEGF-only therapies, and at what cost to payers and patients.
Sanofi Ventures' participation is a detail worth tracking. A pharma corporate venture arm joining a Series A often signals strategic interest that extends beyond financial return. Whether that translates into a partnership or acquisition path later is speculative, but the seat at the cap table is not nothing.
Memento enters development as a privately held company with a well-capitalized syndicate, a licensed asset with prior clinical framing, and a target combination that the field has been watching. The Series A buys time to generate the data that answers whether the dual-mechanism hypothesis holds.